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Both overexpression of PLTP [11±13] and targeted disruption of the PLTP-gene in mice cause dramatic reductions of HDL-cholesterol (HDL-C) in plasma [14] . Different mechanisms are thought to be involved in these apparently conflicting observations: the reduction of HDL-C observed in PLTP ±/± mice could be due to a reduced transfer of surface components from TGRL into HDL, altering the stability of HDL particles [14] . The reduction of HDL-C concentrations with overexpression of PLTP [11] has been explained by an accelerated HDL catabolism.
Obesity is increasingly prevalent in the Western world and is a risk factor for many illnesses, particularly for atherosclerosis and cancer and also for overall mortality [15±18] . Recently, upgrading obesity from a contributing risk factor to a major risk factor for coronary heart disease has been discussed [19] . Obesity is also associated with Type II (non-insulindependent) diabetes mellitus, hypertension and dyslipidaemia characterized by hypertriglyceridaemia and low HDL-C concentrations [20, 21] . Data on PLTP activity in obesity are conflicting [22±24]: in two studies PLTP activity was found increased in obese patients when compared to healthy non-obese subjects [22, 24] , while in another no difference was found between obese and lean individuals [23] . Euglycaemic clamp studies showed a more pronounced suppressive effect of insulin on PLTP activity in healthy subjects than Type II diabetic patients which suggests an association between PLTP activity and insulin resistance [22, 25] .
Therefore, we tested PLTP, one of the key enzymes for HDL metabolism, individually in obesity and in insulin resistance in order to investigate some aspects of lipoprotein metabolism in this clinical setting.
Subjects and methods
Subjects. Altogether 190 subjects, 77 men between 40 and 60 years and 113 women between 50 and 70 years with stable body weight and consuming a typical Western diet participated in the study. All subjects were normolipidaemic with LDL-C below 3.9 mmol/l, TG below 1.71 mmol/l, HDL-C below 0.9 mmol/l in men and below 1.04 mmol/l in women and had fasting glucose concentrations below 6.11 mmol/l. Patients with clinical evidence of coronary heart disease, other heart diseases, vitia cordis, cerebrovascular disorders, peripheral vascular disorders, drug abuse, pregnancy, renal or hepatic diseases, malignancies, thyroid dysfunction and patients taking drugs that could affect lipid metabolism or glucose homeostasis, respectively, were excluded from the study. The study protocol was approved by the local ethics committee. Informed consent was obtained from each participant. Insulin sensitivity. We used the short insulin tolerance test (ITT) [26] . Blood glucose was measured before and 15 min after an intravenous bolus of short-acting insulin (0.1 U/kg body weight). Insulin sensitivity was expressed as k s value (kITT) (% decrease in plasma glucose concentration/minute). Insulin sensitivity was also estimated by the homeostasis model assessment (HOMA) index [27] .
Laboratory measurements. Venous blood was drawn after an overnight fast and plasma was obtained by centrifugation at 3000 rpm for 10 min at 4 C immediately after blood collection. Plasma samples were either used immediately for analysis or were stored frozen at ±80 C. Cholesterol, HDL-C, TG and venous plasma glucose concentrations were measured using commercially available enzymatic kits (Roche Diagnostics, Mannheim, Germany), apolipoprotein A-I and B plasma concentrations were measured using turbidimetric assays (Roche Diagnostics). Fasting plasma insulin concentrations were measured by a microparticle enzyme immunoassay on an IMx analyser (IMx system No.2A10±20, Abbott Diagnostics, Abbott Park, Ill., USA). HbA 1 c values were determined by a commercially available turbidimetric assay (Roche Diagnostics). Plasma leptin concentrations were measured by an enzyme-linked immunosorbent assay according to the manufacturer's instructions (R&D Systems, Wiesbaden, Germany).
Determination of body fat distribution. Areas of abdominal subcutaneous and visceral fat were assessed by computed tomography (CT) scan (Picker CT MXTWIN, Picker International, Cleveland, Ohio, USA) using a single cross-section at position L4/5. Body composition was determined by body impedance analysis (B. I. A. 2000-M, Data Input, Frankfurt, Germany) according to standard protocols.
PLTP activity assay. The ability of plasma to transfer 3 H-dipalmitoyl-phosphatidylcholine ( 3 H-PC) (NEN Life Science Products, Boston, Mass., USA) from phosphatidylcholine (PC) vesicles to HDL 3 was measured as described previously [11, 25, 28, 29] . In brief, the reaction mixture containing 10 mmol of L-a-PC (Sigma, St. Louis, Mo., USA), 2 mCi 3 H-PC and 0.1 mmol of butylated hydroxytoluene (Sigma) was dried down under N 2 and resuspended in 1 ml of 150 mmol/l NaCl, 10 mmol/l TRIS-HCl, 1 mmol/l EDTA (pH 7.4). After sonication of the mixture, lipid aggregates and titanium debris were removed by centrifugation. Four mlitres of plasma were incubated with Statistical analysis. Descriptive data are expressed as means SD. The significance of differences in means between more than two groups was tested by ANOVA with the Bonferroni correction. Correlation coefficients were calculated with Pearson's method. Partial correlation of parameters was used to correct for other parameters. Statistical significance was inferred at a two-tailed p value of less than 0.05. A stepwise regression analysis was done by entering the independent variable with the highest partial correlation coefficient at each step, until no variable remained with an F value of 4 or more. Statistical analyses were done using the statistical software package SPSS for Windows (Version 8.0) (SPSS, Chicago, Ill., USA).
Results
Study population. The study cohort comprised 190 subjects who were subdivided into quartiles according to their BMI (Q1: BMI < 23. Table 1 . As shown in Table 2 , fasting plasma glucose, fasting plasma insulin concentrations and HbA 1 c values were highest in Q4, kITT values were lowest in this group. Lipid parameters of the four subgroups are also summarized in Table 2 . Total cholesterol, TG, LDL-C and HDL-C concentrations were comparable between the four subgroups.
PLTP activity and BMI. PLTP activities were significantly higher in the group with the highest BMI (Q4) (15.10 3.03 mmol´ml ±1´h±1 , n = 48) when compared to the groups Q1 (11.89 2.31 mmolḿ l ±1´h±1 , p < 0.01, n = 48), Q2 (11.86 2.81 mmolḿ l ±1´h±1 , p < 0.01, n = 48) and Q3 (12.81 1.78 mmol´ml ±1´h±1 , p < 0.01, n = 46) (Fig. 1) , while differences in PLTP activity between Q1, Q2 or Q3 did not reach statistical significance.
Correlations. PLTP activity correlated positively with BMI (r = 0.46, p < 0.01), subcutaneous fat area (r = 0.32, p < 0.01), body fat mass (r = 0.39, p < 0.01), plasma leptin concentrations (r = 0.24, p < 0.01) and waist-to-hip ratio (r = 0.16, p = 0.03), respectively. Positive correlations were also found between PLTP activity and fasting plasma insulin concentration (r = 0.28, p < 0.01), fasting plasma glucose concentrations (r = 0.18, p = 0.01) and the HOMA index (r = 0.27, p < 0.01) but not with insulin sensitivity expressed as kITT value ( Fig. 2A) . After correction for kITT values, the positive correlation between PLTP activity and BMI (r = 0.46, p < 0.01) (Fig. 2B) , body fat mass (r = 0.36, p < 0.01), subcutaneous fat area (r = 0.29, p < 0.01) and leptin concentrations (r = 0.20, p = 0.01) persisted. When corrected for the HOMA index, PLTP activity was positively correlated with BMI (r = 0.40, p < 0.01), body fat mass (r = 0.29, p < 0.01), subcutaneous fat area (r = 0.23, p = 0.01) and leptin concentrations (r = 0.17, p = 0.05), respectively. After correction for BMI, waist-to-hip ratio, subcutaneous fat area, visceral fat area, body fat mass and plasma leptin concentrations, respectively, the correlation between PLTP activity and fasting plasma insulin or glucose concentrations and the HOMA index disappeared. As determined by linear regression analysis, BMI was the sole predictor of PLTP activity in plasma (p < 0.01) explaining 22.2 % of the activity in this study (p < 0.01).
PLTP activity and insulin sensitivity. To test for the influence of insulin sensitivity on PLTP activity in obesity, the subjects of the group with the highest BMI (Q4) were subdivided further into tertiles according to insulin sensitivity expressed as kITT value (T1: kITT > 4 %/min, T2: kITT: 2.8±4 %/min, T3: kITT < 2.8 %/min) ( Table 3 ). The groups did not differ in BMI, waist-to-hip ratio, subcutaneous or visceral fat area or body fat mass, respectively. Fasting plasma insulin concentrations increased statistically significantly from T1 to T3 and kITT value significantly decreased from T1 to T3 (Table 4) .
No statistically significant differences in PLTP activities were found between groups T1 (15.70 , n = 16) (Fig. 3) , suggesting that insulin sensitivity does not influence PLTP activity in normolipidaemic, obese, non-diabetic subjects.
When the subjects of the quartiles Q1, Q2 and Q3 were subdivided further into tertiles T1, T2 and T3 according to insulin sensitivity expressed as kITT value, PLTP activity was significantly lower in T3 (lowest kITT value) when compared to T2 in the subjects of the second quartile. In the subjects of the third quartile PLTP activity was statistically significantly higher in the third tertile when compared to the first tertile (data not shown). When each quartile was sub- . PLTP activity was highest in group Q4 (p < 0.01). Q, quartiles of BMI. Means SD Fig. 2 . Correlation between PLTP activity and kITT or BMI value in all study subjects. Note the lack of correlation between PLTP activity and kITT value after correction for BMI, waist-to-hip ratio, body fat mass, subcutaneous fat area, visceral fat area and plasma leptin concentrations, respectively (A) and the significant correlation between PLTP activity and BMI (r = 0.40, p < 0.01) after correction for kITT value (B) divided further into tertiles T1, T2 and T3 according to insulin sensitivity expressed as HOMA index, PLTP activity was similar in each subgroup (data not shown).
Discussion
Obesity, very common in the Western countries, is frequently associated with insulin resistance and dyslipidaemia. Obesity-associated dyslipidaemia is characterized by hypertriglyceridaemia, excessive postprandial lipemia and, as a consequence, low HDL concentrations and the preponderance of small, dense LDL particles [20, 21, 31, 32] . Each of these features is thought to promote atherogenesis [33, 34] . Pronounced postprandial lipemia could be caused in part by impaired postprandial clearance of TGRL in adipose tissue in obese subjects [35] . Another feature of lipoprotein distribution in obesity is a decreased a 1 -HDL fraction accompanied by elevated pre-b 1 -HDL concentrations [36] . Increased pre-b-HDL concentrations were shown to be due to high PLTP activity [11] .
We aimed to test whether obesity affects PLTP activity and, thus, HDL metabolism. To exclude a potential confounding effect of insulin resistance, we controlled for this condition and determined PLTP activity in lean and obese patients with and without insulin resistance. Our data show increased PLTP activity in obese patients compared to lean control subjects. This increase appears to be a consequence of obesity itself and not of insulin resistance.
Because our data suggests that PLTP activity is independent of insulin resistance, the question arises which molecular mechanism could be responsible for increased PLTP activity in obesity. The most common alteration in the lipoprotein profile of obese subjects, i. e., hypertriglyceridaemia, appears not to cause increased PLTP activity according to our data: firstly, only normotriglyceridaemic lean and obese subjects were included in our study and secondly, no correlation between lipoprotein concentrations and PLTP activity was observed. Values are means SD Table 4 . Lipoprotein profile and parameters of glucose homeostasis in the highest quartile of BMI subdivided into tertiles according to the degree of insulin sensitivity On the basis of our results showing a strong correlation between PLTP activity and body fat mass the most straightforward explanation for the increased PLTP activity in obesity appears to be an increased synthesis of the lipid transfer proteins (CETP and PLTP) by the enlarged mass of adipose tissue. Although we are not able to provide data about PLTP mass, others have shown a tight correlation between PLTP mass and enzymatic activity in normolipidaemic, non-diabetic subjects [37] . Further support of the notion that increased PLTP activity is the result of enlarged adipose tissue mass comes from a work showing a positive correlation between PLTP mRNA content in subcutaneous adipose tissue and BMI [4] . Moreover, our results show a strong correlation between PLTP activity and the adipocyte-derived hormone leptin.
In obesity, two enzymes, PLTP and CETP, released from adipose tissue and a variety of other tissues in a ªdose-dependentº manner appear to directly modulate lipoprotein metabolism [3, 4, 38] : enhanced PLTP activity results in a lower HDL-C fraction accompanied by a relative increase in pre-b-HDL [11] . CETP also catalyses the transfer of cholesteryl ester from HDL to TGRL in exchange for TG and leads to an enrichment of HDL and LDL with TG. Hydrolysis of TG-enriched LDL and HDL results in a proatherogenic lipoprotein pattern characterized by the preponderance of small, dense HDL and LDL particles.
In atherogenesis, the role of increased PLTP activity is less clear. Increased PLTP activity [12, 13] is associated with reduced HDL-C concentrations. However, plasma of PLTP-transgenic mice is more efficient than plasma of wild-type mice in preventing the accumulation of intracellular cholesterol in macrophages [11] . Furthermore, increased PLTP activity enhances the formation of pre-b-HDL particles which have an important function in anti-atherogenic reverse cholesterol transport [9, 10] . Although these data are contradictory in part, they do emphasize the involvement of PLTP in atherogenesis.
In conclusion, we show that PLTP activity and, as a consequence, lipoprotein metabolism, especially HDL metabolism, is influenced in normolipidaemic, non-diabetic subjects mainly by BMI rather than by insulin resistance. Our data suggest that obesity itself deserves to be accorded the status of an independent determinant of atherosclerosis. Fig. 3 . PLTP activity in obese patients with different degree of insulin sensitivity. Patients of the highest quartile of BMI were subdivided into three groups according to their insulin sensitivity as measured by the short insulin tolerance test (T1: kITT < 2.8 %/min, T2: kITT 2.8±4.0 %/min, T3: kITT > 4.0 %/ min). No difference in PLTP activity was found between the three groups. T, tertiles of insulin sensitivity. Means SD
